The effect of L-carnitine on lipid metabolism in patients on chronic haemodialysis
| Autor: | F. B. Pedersen, E. Laier, H. F. Larsen, A. Trostmann, Knud Bonnet Yderstræde, C. Dragsholt |
|---|---|
| Předmět: |
Adult
Male medicine.medical_specialty Resuscitation Time Factors Apolipoprotein B medicine.medical_treatment Apolipoproteins A Hyperlipoproteinemia Type IV law.invention Levocarnitine Double-Blind Method Randomized controlled trial Renal Dialysis law Carnitine Internal medicine medicine Humans Aged Clinical Trials as Topic Transplantation biology business.industry Lipid metabolism Middle Aged Lipid Metabolism Endocrinology Nephrology biology.protein Female lipids (amino acids peptides and proteins) Hemodialysis business medicine.drug |
| Zdroj: | University of Southern Denmark Europe PubMed Central |
| Popis: | Twenty-one patients (median 49 years; range 20-72 years) on chronic haemodialysis (median: 54 months; range 16-154 months) were examined in a clinical controlled trial for the effect of carnitine on hyperlipoproteinaemia. Initial values of serum carnitine were within the normal range. Carnitine was added to the dialysis fluid to a final concentration of 100 mumol/l. The trial was carried out for 6 months, and the serum of fasting patients was analysed at monthly intervals for carnitine, triglycerides, HDL-cholesterol, LDL-cholesterol and apolipoprotein A and B. The loss of carnitine to the dialysis fluid also was examined, as was the retained amount in those receiving carnitine. We could not confirm the findings of others that carnitine produces lowering of serum triglycerides and increases of serum HDL-cholesterol. The study was extended for another year with ten patients; however, no change was observed in the lipid pattern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|